HemaSphere (Aug 2023)
P869: UPDATED RESULTS OF A PHASE I, OPEN-LABEL STUDY OF BCMA/CD19 DUAL-TARGETING FASTCAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
- Juan Du,
- Weijun Fu,
- Hua Jiang,
- Baoxia Dong,
- LI Gao,
- LI Liu,
- Jian Ge,
- Aili He,
- Lu LI,
- Jing Lu,
- Xiequn Chen,
- Jia Liu,
- Qi Zhang,
- Jiaping He,
- Lihong Weng,
- Hua Zhang,
- Lianjun Shen,
- Wei Cao,
- Wenling LI
Affiliations
- Juan Du
- 1 Shanghai Chang Zheng Hospital, Hematology, Shanghai, China
- Weijun Fu
- 1 Shanghai Chang Zheng Hospital, Hematology, Shanghai, China
- Hua Jiang
- 1 Shanghai Chang Zheng Hospital, Hematology, Shanghai, China
- Baoxia Dong
- 2 Xijing Hospital, Xi’an, China
- LI Gao
- 3 The Second Affiliated Hospital of Army Medical University, Chongqing, China
- LI Liu
- 4 Tangdu Hospital, Air Force Medical University, Xi’an, China
- Jian Ge
- 5 The First Affiliated Hospital of Anhui Medical University, Hefei, China
- Aili He
- 6 The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
- Lu LI
- 1 Shanghai Chang Zheng Hospital, Hematology, Shanghai, China
- Jing Lu
- 1 Shanghai Chang Zheng Hospital, Hematology, Shanghai, China
- Xiequn Chen
- 2 Xijing Hospital, Xi’an, China
- Jia Liu
- 7 Gracell Biotechnologies Ltd, Shanghai, China
- Qi Zhang
- 7 Gracell Biotechnologies Ltd, Shanghai, China
- Jiaping He
- 7 Gracell Biotechnologies Ltd, Shanghai, China
- Lihong Weng
- 7 Gracell Biotechnologies Ltd, Shanghai, China
- Hua Zhang
- 7 Gracell Biotechnologies Ltd, Shanghai, China
- Lianjun Shen
- 7 Gracell Biotechnologies Ltd, Shanghai, China
- Wei Cao
- 7 Gracell Biotechnologies Ltd, Shanghai, China
- Wenling LI
- 7 Gracell Biotechnologies Ltd, Shanghai, China
- DOI
- https://doi.org/10.1097/01.HS9.0000970380.84060.bf
- Journal volume & issue
-
Vol. 7
p. e84060bf
Abstract
No abstracts available.
